Clinical Trials Logo

Lung Cancer Stage II clinical trials

View clinical trials related to Lung Cancer Stage II.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06060964 Not yet recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

Breathe Easier
Start date: October 2, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the preliminary affects of "Breathe Easier," an evidence-based multi-level mindfulness intervention (i.e., progressive web application) for survivors of lung cancer. The key aims of this study are to (1) Evaluate the feasibility (usability, acceptability intervention adherence) of the "Breathe Easier" and (2) assess the impact of the intervention on dyspnea, fatigue, and quality of life among survivors of lung cancer. Participants in the intervention group will use the "Breathe Easier" progressive web application for a period of 8-weeks, while participants in the control group will receive no intervention. Researchers will compare the intervention and control groups to see if there are salient differences in dyspnea, fatigue, and quality of life between the two groups.

NCT ID: NCT04970043 Not yet recruiting - Clinical trials for Lung Cancer Stage II

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Start date: July 31, 2021
Phase: N/A
Study type: Interventional

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

NCT ID: NCT04375566 Not yet recruiting - Clinical trials for Lung Cancer Stage II

Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-II

Start date: October 4, 2021
Phase:
Study type: Observational

Studies indicate that the majority of early-stage non-small cell lung cancer (NSCLC) patients find it important to be involved in treatment decision making. However, in a recent study it has been reported that about 40% of the participants experienced decision conflict and feel uninformed(1). The investigators therefore developed a patient decision aid (PDA) for stage I-II NSCLC patients, that informs and empowers patients to help decide between stereotactic radiotherapy (SBRT) and surgery.

NCT ID: NCT04108013 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Start date: October 8, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.